IBDEI055 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1882,2)
 ;;=^5002872
 ;;^UTILITY(U,$J,358.3,1883,0)
 ;;=E71.313^^3^57^48
 ;;^UTILITY(U,$J,358.3,1883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1883,1,3,0)
 ;;=3^Glutaric aciduria type II
 ;;^UTILITY(U,$J,358.3,1883,1,4,0)
 ;;=4^E71.313
 ;;^UTILITY(U,$J,358.3,1883,2)
 ;;=^5002873
 ;;^UTILITY(U,$J,358.3,1884,0)
 ;;=E71.314^^3^57^82
 ;;^UTILITY(U,$J,358.3,1884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1884,1,3,0)
 ;;=3^Muscle carnitine palmitoyltransferase deficiency
 ;;^UTILITY(U,$J,358.3,1884,1,4,0)
 ;;=4^E71.314
 ;;^UTILITY(U,$J,358.3,1884,2)
 ;;=^5002874
 ;;^UTILITY(U,$J,358.3,1885,0)
 ;;=E71.318^^3^57^39
 ;;^UTILITY(U,$J,358.3,1885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1885,1,3,0)
 ;;=3^Fatty-Acid Oxidation Disorders NEC
 ;;^UTILITY(U,$J,358.3,1885,1,4,0)
 ;;=4^E71.318
 ;;^UTILITY(U,$J,358.3,1885,2)
 ;;=^5002875
 ;;^UTILITY(U,$J,358.3,1886,0)
 ;;=E71.50^^3^57^89
 ;;^UTILITY(U,$J,358.3,1886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1886,1,3,0)
 ;;=3^Peroxisomal disorder, unspecified
 ;;^UTILITY(U,$J,358.3,1886,1,4,0)
 ;;=4^E71.50
 ;;^UTILITY(U,$J,358.3,1886,2)
 ;;=^5002880
 ;;^UTILITY(U,$J,358.3,1887,0)
 ;;=E71.510^^3^57^114
 ;;^UTILITY(U,$J,358.3,1887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1887,1,3,0)
 ;;=3^Zellweger syndrome
 ;;^UTILITY(U,$J,358.3,1887,1,4,0)
 ;;=4^E71.510
 ;;^UTILITY(U,$J,358.3,1887,2)
 ;;=^128776
 ;;^UTILITY(U,$J,358.3,1888,0)
 ;;=E71.522^^3^57^11
 ;;^UTILITY(U,$J,358.3,1888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1888,1,3,0)
 ;;=3^Adrenomyeloneuropathy
 ;;^UTILITY(U,$J,358.3,1888,1,4,0)
 ;;=4^E71.522
 ;;^UTILITY(U,$J,358.3,1888,2)
 ;;=^276921
 ;;^UTILITY(U,$J,358.3,1889,0)
 ;;=E71.529^^3^57^113
 ;;^UTILITY(U,$J,358.3,1889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1889,1,3,0)
 ;;=3^X-linked adrenoleukodystrophy, unspecified type
 ;;^UTILITY(U,$J,358.3,1889,1,4,0)
 ;;=4^E71.529
 ;;^UTILITY(U,$J,358.3,1889,2)
 ;;=^5002886
 ;;^UTILITY(U,$J,358.3,1890,0)
 ;;=E71.548^^3^57^90
 ;;^UTILITY(U,$J,358.3,1890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1890,1,3,0)
 ;;=3^Peroxisomal disorders NEC
 ;;^UTILITY(U,$J,358.3,1890,1,4,0)
 ;;=4^E71.548
 ;;^UTILITY(U,$J,358.3,1890,2)
 ;;=^5002891
 ;;^UTILITY(U,$J,358.3,1891,0)
 ;;=E88.40^^3^57^78
 ;;^UTILITY(U,$J,358.3,1891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1891,1,3,0)
 ;;=3^Mitochondrial metabolism disorder, unspecified
 ;;^UTILITY(U,$J,358.3,1891,1,4,0)
 ;;=4^E88.40
 ;;^UTILITY(U,$J,358.3,1891,2)
 ;;=^5003030
 ;;^UTILITY(U,$J,358.3,1892,0)
 ;;=E88.41^^3^57^72
 ;;^UTILITY(U,$J,358.3,1892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1892,1,3,0)
 ;;=3^MELAS syndrome
 ;;^UTILITY(U,$J,358.3,1892,1,4,0)
 ;;=4^E88.41
 ;;^UTILITY(U,$J,358.3,1892,2)
 ;;=^278244
 ;;^UTILITY(U,$J,358.3,1893,0)
 ;;=E88.42^^3^57^73
 ;;^UTILITY(U,$J,358.3,1893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1893,1,3,0)
 ;;=3^MERRF syndrome
 ;;^UTILITY(U,$J,358.3,1893,1,4,0)
 ;;=4^E88.42
 ;;^UTILITY(U,$J,358.3,1893,2)
 ;;=^278246
 ;;^UTILITY(U,$J,358.3,1894,0)
 ;;=E88.49^^3^57^79
 ;;^UTILITY(U,$J,358.3,1894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1894,1,3,0)
 ;;=3^Mitochondrial metabolism disorders NEC
 ;;^UTILITY(U,$J,358.3,1894,1,4,0)
 ;;=4^E88.49
 ;;^UTILITY(U,$J,358.3,1894,2)
 ;;=^5003031
 ;;^UTILITY(U,$J,358.3,1895,0)
 ;;=H49.819^^3^57^63
 ;;^UTILITY(U,$J,358.3,1895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1895,1,3,0)
 ;;=3^Kearns-Sayre syndrome, unspecified eye
 ;;^UTILITY(U,$J,358.3,1895,1,4,0)
 ;;=4^H49.819
 ;;^UTILITY(U,$J,358.3,1895,2)
 ;;=^5006202
 ;;^UTILITY(U,$J,358.3,1896,0)
 ;;=E66.9^^3^57^85
 ;;
 ;;$END ROU IBDEI055
